Mysterious drone activity triggers massive 1,366% surge

If mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%.

👉 Click here now to see how this signal works.

Sean A. McCarthy net worth and biography

Sean McCarthy Biography and Net Worth

CEO of CytomX Therapeutics

Dr. McCarthy joined CytomX in 2010 as chief business officer and has served as chief executive officer since 2011 and CEO and chairman since 2019. Previously, Dr. McCarthy was a transactional partner at Pappas Ventures. Prior to Pappas, Sean headed business development and strategy at SGX Pharmaceuticals, a structure-based drug discovery company focused in oncology. Earlier in his career he served in various R&D roles at Millennium Pharmaceuticals. Dr. McCarthy is an author on multiple peer-reviewed scientific publications and issued patents. He is a member of the board of directors of Oncoresponse, Inc. and a member of the board of directors and executive committee of California Life Sciences. Dr. McCarthy received his Bachelor of Science degree in biochemistry and pharmacology at King’s College, University of London. He also received an MBA from the Rady School of Management at UCSD and a D. Phil. in cancer biology from St. John’s College, University of Oxford.

What is Sean A. McCarthy's net worth?: The estimated net worth of Sean A. McCarthy is at least $743,371.63 as of August 20th, 2024. Dr. McCarthy owns 657,851 shares of CytomX Therapeutics stock worth more than $743,372 as of December 26th. This net worth approximation does not reflect any other investments that Dr. McCarthy may own. Additionally, Dr. McCarthy receives a salary of $1,030,000.00 as CEO at CytomX Therapeutics. Learn More about Sean A. McCarthy's net worth.
How old is Sean A. McCarthy?: Dr. McCarthy is currently 57 years old. Learn More on Sean A. McCarthy's age.
What is Sean A. McCarthy's salary?: As the CEO of CytomX Therapeutics, Inc., Dr. McCarthy earns $1,030,000.00 per year. Learn More on Sean A. McCarthy's salary.
How do I contact Sean A. McCarthy?: The corporate mailing address for Dr. McCarthy and other CytomX Therapeutics executives is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. CytomX Therapeutics can also be reached via phone at (605) 515-3185 and via email at [email protected]. Learn More on Sean A. McCarthy's contact information.
Has Sean A. McCarthy been buying or selling shares of CytomX Therapeutics?: Sean A. McCarthy has not been actively trading shares of CytomX Therapeutics during the last quarter. Most recently, Sean A. Mccarthy sold 13,898 shares of the business's stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $1.23, for a transaction totalling $17,094.54. Following the completion of the sale, the chief executive officer now directly owns 657,851 shares of the company's stock, valued at $809,156.73. Learn More on Sean A. McCarthy's trading history.
Are insiders buying or selling shares of CytomX Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 7 times. They sold a total of 55,087 shares worth more than $97,877.65. The most recent insider tranaction occured on August, 20th when insider Jeffrey B Landau sold 4,181 shares worth more than $5,142.63. Insiders at CytomX Therapeutics own 7.0% of the company. Learn More about insider trades at CytomX Therapeutics.
Information on this page was last updated on 8/20/2024.

Sean A. McCarthy Insider Trading History at CytomX Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/20/2024	Sell	13,898	$1.23	$17,094.54	657,851
3/19/2024	Sell	20,223	$2.09	$42,266.07	524,481
12/20/2023	Sell	13,551	$1.38	$18,700.38	454,704
9/22/2023	Sell	14,601	$1.30	$18,981.30	430,755
3/16/2023	Sell	7,121	$1.88	$13,387.48	388,821
7/20/2022	Sell	14,911	$1.42	$21,173.62	290,942
6/16/2021	Sell	100,000	$7.04	$704,000.00	7,849
3/31/2021	Sell	100,000	$7.49	$749,000.00	306,894
5/12/2020	Sell	36,000	$15.00	$540,000.00	120,306
11/2/2018	Sell	6,526	$15.00	$97,890.00
9/4/2018	Sell	13,052	$21.86	$285,316.72	95,115
7/5/2018	Sell	4,497	$25.06	$112,694.82	86,560
7/3/2018	Sell	2,028	$25.09	$50,882.52	84,091
7/2/2018	Sell	13,052	$23.42	$305,677.84
5/1/2018	Sell	19,578	$26.55	$519,795.90	24,221
1/5/2018	Sell	6,526	$25.01	$163,215.26	11,169
1/2/2018	Sell	13,052	$21.04	$274,614.08	17,695
12/1/2017	Sell	14,340	$20.60	$295,404.00
11/1/2017	Sell	14,342	$19.86	$284,832.12	18,587
10/4/2017	Sell	19,120	$24.13	$461,365.60	23,365
10/2/2017	Sell	9,562	$18.57	$177,566.34
9/1/2017	Sell	9,930	$17.32	$171,987.60	14,175
8/31/2017	Sell	18,756	$17.50	$328,230.00	23,001
8/9/2017	Sell	4,781	$15.00	$71,715.00	9,026
7/3/2017	Sell	4,781	$15.52	$74,201.12	9,026
6/26/2017	Sell	4,481	$15.00	$67,215.00	8,726
6/5/2017	Sell	300	$15.00	$4,500.00	4,545
5/1/2017	Sell	4,781	$15.70	$75,061.70	6,760
4/4/2017	Sell	9,562	$17.22	$164,657.64	6,760
3/20/2017	Sell	14,343	$19.60	$281,122.80	16,322
3/3/2017	Sell	14,343	$15.00	$215,145.00	16,322

Sean A. McCarthy Buying and Selling Activity at CytomX Therapeutics

CytomX Therapeutics Company Overview

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.13

$1.06

$1.15

50 Day Range

MA: $1.06

$0.86

$1.29

2 Week Range

Now: $1.13

$0.83

$5.85

Volume

1,166,101 shs

Average Volume

2,423,248 shs

Market Capitalization

$88.43 million

P/E Ratio

6.65

Dividend Yield

N/A

Beta

1.07

Last time you’ll see this priced at $1.00

From StocksToTrade | Ad

When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore!

Click here to review Tim’s special Holiday offer before it’s too late.

Sean McCarthy Biography and Net Worth

What is Sean A. McCarthy's net worth?

How old is Sean A. McCarthy?

What is Sean A. McCarthy's salary?

How do I contact Sean A. McCarthy?

Has Sean A. McCarthy been buying or selling shares of CytomX Therapeutics?

Are insiders buying or selling shares of CytomX Therapeutics?